Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB) (PTR-01-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03752905
Recruitment Status : Recruiting
First Posted : November 26, 2018
Last Update Posted : February 8, 2019
Sponsor:
Information provided by (Responsible Party):
Phoenix Tissue Repair, Inc.

Brief Summary:

Protocol PTR-01-001 is a Phase 1/2 study of PTR-01.

The study is divided into an up to 4-week Screening Period, a 10-week Treatment Period and an 8-week Follow-up Period.

Cohorts 1, 2 and 3 will consist of 2, 4 and 8 patients respectively. Each cohort will consist of patients divided into two groups (Group 1 and Group 2) randomized in a 1:1 ratio. Patients in Group 1 will receive three doses of active drug followed by 3 doses of saline control. Patients in Group 2 will receive three doses of saline control followed by 3 doses of active drug.

Cohort 1 patients randomized to Group 1 will receive 3 doses of active treatment (PTR-01) at a dose of 0.1 mg/kg followed by 3 doses of saline control for a total of 6 doses. Cohort 1 patients randomized to Group 2 will receive 3 doses of saline control followed by 3 doses of active treatment (PTR-01) at a dose of 0.1 mg/kg for a total of 6 doses.


Condition or disease Intervention/treatment Phase
Recessive Dystrophic Epidermolysis Bullosa Drug: PTR-01 Drug: Normal saline Phase 1 Phase 2

Detailed Description:

Protocol PTR-01-001 is a saline-controlled, single and repeat dose, dose-escalation, crossover study designed to determine the safety, tolerability, tissue kinetics, pharmacodynamics and preliminary efficacy of PTR 01.

The study is divided into three periods: an up to 4-week Screening Period, a 10-week Treatment Period and an 8-week Follow-up Period. During the Screening Period and Follow-up Period there will be no study drug treatment.

During the Treatment Period a total of 3 doses of PTR-01 and 3 doses of saline control will be administered to patients for a total of 6 doses over a 10-week period in three cohorts dosed at 0.1, 0.3 and 1.0 mg/kg (active drug). Fourteen patients with a diagnosis of RDEB and a history of at least one chronic wound will be enrolled. Those patients who do not have documentation of genetic analysis and IF staining will have blood for genetic analysis and a biopsy for IF staining prior to enrollment (both required).

Cohorts 1, 2 and 3 will consist of 2, 4 and 8 patients respectively. Each cohort will consist of patients divided into two groups (Group 1 and Group 2) randomized in a 1:1 ratio. Patients will receive doses 2 weeks apart. Patients in Group 1 will receive three doses of active drug followed by 3 doses of saline control. Patients in Group 2 will receive three doses of saline control followed by 3 doses of active drug. This cross-over design will yield a total of 14 patients all of whom will receive active drug and saline control.

Prior to randomization, patients will complete a Screening Period to assess the extent and impact of skin disease involvement and the chronicity of at least one wound. Only patients who meet all of the eligibility criteria will be randomized for treatment.

Cohort 1 patients randomized to Group 1 will receive 3 doses of active treatment (PTR-01) at a dose of 0.1 mg/kg followed by 3 doses of saline control for a total of 6 doses. Cohort 1 patients randomized to Group 2 will receive 3 doses of saline control followed by 3 doses of active treatment (PTR-01) at a dose of 0.1 mg/kg for a total of 6 doses. After the last patient in Cohort 1 has received their fifth dose and safety labs for all patients have been reviewed by the Data Safety Monitoring Board (DSMB), the next cohort may be enrolled. This same schedule and safety review process will be followed for all subsequent dosing cohorts, with Cohort 2 and Cohort 3 receiving 0.3 and 1.0 mg/kg respectively.

Efficacy assessments will be performed prior to first dose of therapy (at the end of the Screening Period), after the last dose of study drug in Period 1, after the last dose of study drug in Period 2 of the Treatment Period and 2 weeks (Day 85) after the last dose of study drug (at the end of the Follow-up Period).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Randomized, Saline-Controlled, Single-Blind, Multiple Ascending Dose, Dose-Escalation, Multi-Center
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Single-blind
Primary Purpose: Treatment
Official Title: A Phase 1/2 Randomized, Saline-Controlled, Single-Blind, Multiple Ascending Dose, Dose-Escalation, Multi-Center Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Actual Study Start Date : January 9, 2019
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : December 31, 2019


Arm Intervention/treatment
Experimental: PTR-01 0.1 mg/kg
Three intravenous infusions of PTR-01 at 0.1 mg/kg with doses 2 weeks apart.
Drug: PTR-01
Recombinant human collagen 7 (rC7)
Other Name: Recombinant human collagen 7 (rC7)

Experimental: PTR-01 0.3 mg/kg
Three intravenous infusions of PTR-01 at 0.3 mg/kg with doses 2 weeks apart.
Drug: PTR-01
Recombinant human collagen 7 (rC7)
Other Name: Recombinant human collagen 7 (rC7)

Experimental: PTR-01 1.0 mg/kg
Three intravenous infusions of PTR-01 at 1.0 mg/kg with doses 2 weeks apart.
Drug: PTR-01
Recombinant human collagen 7 (rC7)
Other Name: Recombinant human collagen 7 (rC7)

Placebo Comparator: Normal Saline
Saline control to mimic PTR-01.
Drug: Normal saline
Saline control




Primary Outcome Measures :
  1. Incidence of treatment-emergent adverse events [ Time Frame: Up to Day 127 ]
    The primary endpoint of this study is safety and tolerability, as assessed by treatment-emergent adverse events, infusion-associated reactions (IAR) and immunogenicity


Secondary Outcome Measures :
  1. To measure the peak serum concentration (Cmax) of PTR-01 [ Time Frame: Pre-dose, 15 minutes, 60 minutes, 2 hours, 4 hours, 8 hours and 24 hours post-dose ]
    Pharmacokinetic parameter estimates of Cmax

  2. To measure the time to peak concentration (Tmax) of PTR-01 [ Time Frame: Pre-dose, 15 minutes, 60 minutes, 2 hours, 4 hours, 8 hours and 24 hours post-dose ]
    Pharmacokinetic parameter estimates of Tmax

  3. To measure the area under the curve (AUC) of PTR-01 [ Time Frame: Pre-dose, 15 minutes, 60 minutes, 2 hours, 4 hours, 8 hours and 24 hours post-dose ]
    Pharmacokinetic parameter estimates of AUC

  4. To measure the clearance of PTR-01 [ Time Frame: Pre-dose, 15 minutes, 60 minutes, 2 hours, 4 hours, 8 hours and 24 hours post-dose ]
    Pharmacokinetic parameter estimates of clearance

  5. To measure the half-life (t1/2) of PTR-01 [ Time Frame: Pre-dose, 15 minutes, 60 minutes, 2 hours, 4 hours, 8 hours and 24 hours post-dose ]
    Pharmacokinetic parameter estimates of t1/2

  6. Change from Baseline in rC7 [ Time Frame: Screening and Day 127 ]
    Change in rC7 on skin biopsy by immunofluorescence (IF)

  7. Change from Baseline in anchoring fibrils [ Time Frame: Screening and Day 127 ]
    Change in anchoring fibrils on skin biopsy by electron microscopy (EM)

  8. Duration of rC7 residence in tissue [ Time Frame: Screening and Day 127 ]
    Duration of rC7 residence in tissue by skin biopsy


Other Outcome Measures:
  1. Change from Baseline in suction blister time [ Time Frame: Baseline and Day 127 ]
    Change from Baseline in suction blister time (as compared to placebo and historical controls)

  2. Change from Baseline in target wound size [ Time Frame: Baseline and Day 127 ]
    Change from Baseline in target wound size (percent healing from Baseline)

  3. Change from Baseline in healing of up to 5 chronic wounds [ Time Frame: Baseline and Day 127 ]
    Change in healing of up to 5 wounds that chronically heal and reopen

  4. Change from Baseline in patient reported outcomes as assessed by the Leuven Itch Scale (LIS) [ Time Frame: Baseline and Day 127 ]
    Change from Baseline in patient reported outcomes

  5. Change from Baseline in patient reported outcomes as assessed by the pruritus-specific quality-of-life instrument ("ItchyQoL") [ Time Frame: Baseline and Day 127 ]
    Change from Baseline in patient reported outcomes

  6. Change from Baseline in patient reported outcomes as assessed by the Quality of Life in Epidermolysis Bullosa (QOLEB) Questionnaire [ Time Frame: Baseline and Day 127 ]
    Change from Baseline in patient reported outcomes

  7. Change from Baseline in patient reported outcomes as assessed by the full Health Assessment Questionnaire (HAQ) [ Time Frame: Baseline and Day 127 ]
    Change from Baseline in patient reported outcomes

  8. Change from Baseline in the biochemical marker albumin [ Time Frame: Screening and Day 127 ]
    Change from Baseline in biochemical markers of disease (albumin)

  9. Change from Baseline in the biochemical marker iron [ Time Frame: Screening and Day 127 ]
    Change from Baseline in biochemical markers of disease (iron

  10. Change from Baseline in the biochemical marker total iron binding capacity [ Time Frame: Screening and Day 127 ]
    Change from Baseline in biochemical markers of disease (total iron binding capacity)

  11. Change from Baseline in the biochemical marker hemoglobin [ Time Frame: Screening and Day 127 ]
    Change from Baseline in biochemical markers of disease (hemoglobin)

  12. Change from Baseline in the biochemical marker hematocrit [ Time Frame: Screening and Day 127 ]
    Change from Baseline in biochemical markers of disease (hematocrit)

  13. Change from Baseline in the biochemical marker total protein [ Time Frame: Screening and Day 127 ]
    Change from Baseline in biochemical markers of disease (total protein)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Be at least 18 years of age.
  2. Has signed the current approved informed consent form.
  3. Has a diagnosis of RDEB based on genetic analysis showing two confirmed RDEB type VII collagen mutations consistent with a recessive inheritance pattern.
  4. Has the presence of some but deficient C7 staining at the dermal-epidermal junction (DEJ) by IF.
  5. Has at least 1 unhealed wound ≥ 20 cm2 for at least 6 weeks at the Screening Visit.
  6. Agrees to use contraception as follows:

    • For women of childbearing potential (WOCBP) agrees to use highly effective contraceptive (including abstinence) methods from Screening, through the study, and for at least 10 weeks after the last dose of study drug. Non-childbearing potential is defined as a female who meets either of the following criteria: age ≥50 years and no menses for at least 1 year or documented hysterectomy, bilateral tubal ligation, or bilateral oophorectomy (see Section 7.4.1.2 for details on the definition of non-childbearing potential).
    • For males, agrees to use a condom with any WOCBP sexual partner from Day 1 of study treatment, through the study, and at least 10 weeks after the last dose of study drug.
  7. Be willing and able to comply with this protocol.

Exclusion Criteria:

  1. Has known systemic hypersensitivity to any of the inactive ingredients in PTR-01.
  2. Is pregnant or nursing.
  3. Has received in the last six months any investigational product.
  4. Is anticipated to receive new regimens of antibiotics or other anti-infectives during the trial.
  5. Has any other medical or personal condition that, in the opinion of the Investigator, may potentially compromise the safety or compliance of the patient, or may preclude the patient's successful completion of the clinical study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03752905


Contacts
Layout table for location contacts
Contact: Ramsey Johnson, MSM 978-726-1478 ramsey@phoenixtissuerepair.com
Contact: Theresa Podrebarac, MD 857-498-0977 theresa@phoenixtissuerepair.com

Locations
Layout table for location information
United States, California
Stanford University Recruiting
Redwood City, California, United States, 94063
Contact: Melissa Barriga    650-850-1674    mbarriga@stanford.edu   
Principal Investigator: Jean Tang, MD, PhD         
Sub-Investigator: Peter Marinkovich, MD         
Sponsors and Collaborators
Phoenix Tissue Repair, Inc.
Investigators
Layout table for investigator information
Study Director: Theresa Podrebarac, MD Phoenix Tissue Repair

Additional Information:
Layout table for additonal information
Responsible Party: Phoenix Tissue Repair, Inc.
ClinicalTrials.gov Identifier: NCT03752905     History of Changes
Other Study ID Numbers: PTR-01-001
First Posted: November 26, 2018    Key Record Dates
Last Update Posted: February 8, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There are currently no plans to share individual participant data with other researchers.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Phoenix Tissue Repair, Inc.:
RDEB

Additional relevant MeSH terms:
Layout table for MeSH terms
Epidermolysis Bullosa
Epidermolysis Bullosa Dystrophica
Skin Abnormalities
Congenital Abnormalities
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Skin Diseases, Vesiculobullous
Collagen Diseases
Connective Tissue Diseases